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As breast volume may be associated with heart cancer risk, we studied the relationship between breast volume, CYP1A2*1F and
coffee intake. Among healthy premenopausal non-hormone users, 3þ cups per day was associated with lower volume only in
C-allele carriers (Pinteraction¼0.02), which is consistent with reports that coffee protects only C-allele carriers against breast cancer.
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A recent study reported that coffee reduced the risk of breast
cancer in BRCA1 carriers with the CYP1A2*1F C-allele but not in
those with the CYP1A2*1F A/A genotype (Kotsopoulos et al, 2007).
Another study found significantly lower coffee consumption in
sporadic breast cancer cases with at least one C-allele compared
with the A/A genotype (Ba ˚geman et al, 2008) in spite of the fact
that coffee consumption is similar across CYP1A2*1F genotypes in
the general population (Cornelis et al, 2006). Some studies (Vatten
et al, 1990; Baker et al, 2006; Nkondjock et al, 2006; Ganmaa et al,
2008), but not all (Rosenberg et al, 1985; Vatten et al, 1990;
McLaughlin et al, 1992; Stensvold and Jacobsen, 1994; Michels
et al, 2002), have reported that moderate-to-high coffee consump-
tion protects against breast cancer, though a mechanism is
unknown. None of these studies took CYP1A2*1F into account.
Coffee is metabolised by the CYP1A2 enzyme, which also plays a
key role in oestrogen metabolism (Le Marchand et al, 1997; Lee
et al, 2003). Coffee contains not only caffeine but also
phytooestrogens that can interact with and even block the
oestrogen receptor (Magee and Rowland, 2004). Women with high
coffee intake and the highly inducible CYP1A2*1F A/A genotype
(Sachse et al, 1999) have a high 2-hydroxyoestrone (2-OHE1) to
16a-OHE1 ratio (Jernstro ¨m et al, 2003; Bradlow et al, 2006; Klug
et al, 2006). 2-Hydroxyoestrone is a weak oestrogen (Schneider
et al, 1984), whereas 16a-OHE1 is procarcinogenic (Telang
et al, 1992). In line with this, we found that breast volume in
breast cancer patients was significantly higher in women with a
lower 2-OHE to 16a-OHE1 ratio (Klug et al, 2006). Coffee also
affects testosterone and SHBG levels (Ferrini and Barrett-Connor,
1996; Nagata et al, 1998). Although hormonal regulation of
breast tissue has been extensively studied, little is known about
hormones, genes, diet influence, density, size and diseases of
the breast.
Mammographic density is a strong risk factor for breast cancer
(Boyd et al, 2005), the risk increasing with larger percentage density.
The non-inducible CYP1A2*1F C-allele was associated with the
percent density in normal-weight postmenopausal women not using
hormone therapy (Takata et al, 2007). CYP1A2 enzyme activity has
also been associated with density (Hong et al,2 0 0 4 ) ,a n dc o f f e e
induces CYP1A2 enzyme activity (Djordjevic et al, 2007). There is
no direct correlation between breast density and size after
adjustment for waist-to-hip ratio and BMI (Beijerinck et al, 1995).
However, a larger breast size has been associated with increased
breast cancer risk (Kato et al, 1995), especially in lean women
(Kusano et al, 2006) or in women with proliferative breast disease
(Dupont and Page, 1987). We therefore investigated whether coffee
intake was associated with breast volume in young women and
whether any association was modified by the CYP1A2*1F genotype.
MATERIALS AND METHODS
A total of 269 young healthy Swedish women from breast cancer
high-risk families volunteered to participate in this study between
1996 and 2006. The study population has previously been
described in detail (Hietala et al, 2008). The Ethics Committee of
Lund University approved the study. All women signed a written
informed consent.
The questionnaire included questions on reproductive factors,
the use of hormonal contraceptives, smoking, coffee consumption
and so on. One large cup (approximately 300ml) was counted as
two traditional cups of coffee (approximately 150ml). Blood
samples and body measurements were collected both during
menstrual cycle days 5–10 and days 18–23. Breast volumes were
measured while the woman was on her hands and knees with the
breasts hanging down. The volume was approximated to a pyramid
(base area height/3). Total breast volume, that is the sum of the
right and left breast volumes, was calculated in each visit.
Mutation testing of the BRCA1 and BRCA2 genes was not
performed as part of this study and carrier status was obtained
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2008). CYP1A2*1F analysis (rs762551) PCR primers 50-AGGTAT
CAGCAGAAAGCCAGCAC and 50-GCTGAGGGTTGAGATGGAGA
CAT were used as described earlier (Ba ˚geman et al, 2008). Thirty-
eight samples were run in duplicate with 100% concordance.
Oestradiol was analysed with Elecsys system 1010/2010 in EDTA
plasma. This system uses a competitive immunoassay with a
polyclonal antibody directed towards 17-b oestradiol. Intra-assay
variation ranged from 1.9 to 5.7% and the inter-assay variation
varied from 2.3 to 6.2%.
Testosterone, SHBG and progesterone in EDTA plasma were
measured by electrochemiluminescent immunoassay by Elecsys
1010/2010 Modular analytics E170 analyser with the Roche Elecsys
1010/2010 (Roche Diagnostics, Mannheim, Germany). The intra-
assay variation was 2.5–6.8% for testosterone, 1.8–4.0% for SHBG
and 1.8–4.8% for progesterone. Insulin-like growth factor (IGF)-1
was analysed in EDTA plasma with a radioimmunoassay method at
Karolinska Hospital, Stockholm, Sweden as described earlier (Bang
et al, 1991; Jernstro ¨m et al, 2005). IGFBP-3 was analysed with the
IMMULITE 2000 solid-phase enzyme-labelled chemiluminescent
immunometric assay as described earlier (Jernstro ¨m et al, 2006).
The statistical software programs SPSS13.0 and STATA 10.0
were used. Breast volumes and weights were not normally
distributed and were transformed using the natural logarithm
(ln). The CYP1A2*1F genotype was classified into two groups (A/A
or any C-allele). An interaction term was calculated between
CYP1A2*1F and coffee (3þ cups per day). Multivariate linear
regression analyses were performed to evaluate the interaction
between CYP1A2*1F and coffee on breast volume, and further
adjusted for family clustering using the cluster option of the
logistic command in STATA. Geometric means of standardised
breast volumes and 95% prediction intervals were calculated. The
breast volumes were standardised at age 29 years, weight (ln67kg),
non-smoking and nulliparity. Multivariate logistic regression was
used to analyse the association between coffee and hormone and
growth factor levels. A P-value of o0.05 was taken to be
significant. All P-values were two sided.
RESULTS
Characteristics of the 269 women and CYP1A2*1F genotypes
are presented in Table 1. CYP1A2*1F were available for 267 of the
269 women. CYP1A2*1F did not differ according to BRCA1/2
mutation status (Table 2). Coffee consumption did not signifi-
cantly differ between the CYP1A2*1F after adjusting for age and
smoking.
Total breast volumes during menstrual cycle days 18–23 were
available for 255 women who were not currently breast-feeding
and without previous breast surgeries. Age-adjusted coffee
consumption was positively associated with current smoking
(Po0.0001), but not with nulliparity or current hormonal contra-
ception. Total breast volumes were positively associated with
weight (b¼2.119; Po0.0001), but not with age, current hormonal
contraception, nulliparity, current smoking or CYP1A2*1F.
We stratified the women according to the use of hormonal
contraceptives as this changes endogenous hormone levels (Jern-
stro ¨m and Olsson, 1994; Jernstro ¨m et al, 1997, 2005), influences
breast volumes in nulliparous women (Jernstro ¨m and Olsson, 1997)
and reduces the CYP1A2 enzyme activity (Rietveld et al,1 9 8 4 ) .
Among the non-users, of whom 145 had available breast
volumes and CYP1A2*1F genotypes, the association between a
moderate-to-high coffee consumption (3þ cups per day) and
breast volume was significantly modified by CYP1A2*1F genotype.
Among women carrying at least one C-allele, moderate-to-high
consumption was associated with lower standardised breast
volumes compared with low consumption (896 vs 749ml) whereas
the standardised volumes were somewhat larger in women with
moderate-to-high coffee consumption and the A/A genotype (797
vs 847ml) (b¼ 0.303; Pinteraction¼0.02) (Figure 1). The inter-
action remained significant after further adjustment for BRCA1/2
mutation status (b¼ 0.304; P¼0.02) and after exclusion of
women who currently smoked or used snuff (b¼ 0.328;
P¼0.03). The women belonged to 105 different families. The
interaction remained significant after adjustment for family
clustering (P¼0.03).
Table 1 Baseline characteristics of the 269 women included in the study
All women (N¼269) CYP1A2*1F A/A (N¼136) CYP1A2*1F any C (N¼131)
Median (inter quartile range) or %
Year of birth 1970 (1965–1979) 1970 (1965–1975) 1970 (1964–1976)
Age at baseline (years) 29 (24–34) 29 (24–33) 30 (24–36)
Age at menarche (years)
a 13 (12–13.4) 13 (12–13) 13 (12–14)
Age at first birth in parous women (years) 24.5 (22–28) 24 (23–27) 25 (22–28)
Nulliparous (%) 52 54 49
Ever smoker (%)
a 42 41 42
Current smoker (%)
a 23 24 22
Hormonal contraceptive use, ever (%) 92.5 93 92
Current hormonal contraceptive use (%) 42 48 36
Daily coffee intake, cups (%)
None (32.3) (31.6) (32.8)
o1.0 (3.0) (2.9) (3.1)
1.0–1.9 (5.9) (7.6) (4.6)
2.0–2.9 (17.1) (16.9) (16.8)
3.0–3.9 (6.7) (5.1) (8.4)
4.0–4.9 (11.5) (15.4) (7.6)
5.0–5.9 (5.6) (4.4) (6.9)
6+ (17.8) (16.2) (19.8)
Height (cm)
b 168 (164–172) 168 (164–173) 168 (164–172)
Weight (kg)
b 64 (58–74) 64 (58–75) 65 (58–73)
BMI (kg/m
2)
b 22.8 (20.9–25.6) 22.7 (20.8–26.2) 22.8 (20.9–24.9)
Waist-to-hip ratio
b 0.76 (0.73–0.80) 0.77 (0.73–0.80) 0.75 (0.73–0.80)
Total breast volume (ml)
c 756 (537–1101) 711 (555–1167) 777 (531–1040)
BMI¼body mass index.
aOne woman had not answered the question about age at menarche and the question about smoking.
bThe body measurements were taken 5–10 days
before the predicted onset of the next menstrual period, that is during cycle days 18–23 in most women.
cTotal breast volumes were available for 255 women who were not
currently breast-feeding or had undergone previous breast surgeries.
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SHBG, IGF-1 and IGFBP-3, obtained during the visit when the
breast volumes were measured, were available for 139 women with
data on breast volumes and CYP1A2*1F. In this subgroup, the
interaction between coffee consumption and CYP1A2*1F genotype
on breast volume was somewhat stronger (b¼ 0.341;
Pinteraction¼0.007) and became even stronger after further adjust-
ment for hormone and growth factor levels (b¼ 0.401;
Pinteraction¼0.002).
Among current hormonal contraceptive users, coffee consumption
was not associated with breast volume and there was no significant
interaction between coffee and CYP1A2*1F on breast volume.
DISCUSSION
Our main finding was a significant interaction between coffee
consumption, CYP1A2*1F genotype and breast volume among
young healthy women who did not use hormonal contraceptives.
This interaction was mainly driven by the fact that a moderate-to-
high coffee intake was associated with lower breast volume in
women with the C-allele. No association between coffee and breast
volumes was observed in women with the CYP1A2*1F A/A
genotype or in women who currently used hormonal contra-
ception. As hormonal contraceptives lower the CYP1A2 enzyme
activity (Rietveld et al, 1984), the latter observation was expected.
In this study, approximately 50% of the women carried the
CYP1A2*1F A/A genotype, which is consistent with reported
frequencies (Sachse et al, 1999; Nordmark et al, 2002). CYP1A2*1F
is located in intron 1 and may not directly be associated with
enzyme activity, but is rather linked to other polymorphisms with
regulatory properties (Sachse et al, 1999). Coffee has been reported
to predict 4% of the variation in CYP1A2 enzyme activity
(Le Marchand et al, 1997).
In this study, breast volume was measured and approximated to
a pyramid for practical reasons. A more exact procedure may have
been to use water displacement, which we tried, but was
impractical and less reproducible. Using bra cup size as a
measurement of breast volume is less satisfactory, as cup-size
labelling is not standardised (Ringberg et al, 2006).
Neither bra cup size nor breast volume reflects how much of the
women’s breast volume consists of breast parenchyma and how
much is fat. A high BMI is positively correlated with larger cup sizes
(Hall et al, 1999), which is in line with our findings. Others have
reported that larger breasts consist of proportionally more fat and
less parenchyma than smaller breasts in premenopausal women
(Beijerinck et al, 1995; Kato et al, 1995). Most of our women were
too young to have undergone mammography. We were thus unable
to address whether coffee was associated with density, which is a
stronger predictor of breast cancer risk than breast volume.
As coffee consumption was associated with lower breast volume
among carriers of the C-allele with little effect among homozygous
A/A carriers, mechanisms other than the induction of the CYP1A2
enzyme may be at play. Caffeine is the only major compound in
coffee that is known to be metabolised by CYP1A2 and the effect
could be attributed to the prolonged exposure of caffeine among
C-allele carriers, as caffeine inhibits cell proliferation in mouse
epidermal JB6 cells (Hashimoto et al, 2004).
Intake of caffeine has been positively associated with SHBG
levels (Nagata et al, 1998) and inversely associated with bioavail-
able testosterone (Ferrini and Barrett-Connor, 1996), but
CYP1A2*1F was not analysed. In this study, we did not observe
any significant associations between coffee intake and hormone
and growth factor levels. However, bioavailable testosterone levels
were positively associated with breast volumes in both groups
(data not shown). In contrast to our earlier study, we did not find
that hormonal contraception significantly influenced breast
volume (Jernstro ¨m and Olsson, 1997). In this study, measured
hormone levels did not explain the observed interaction between
coffee and CYP1A2*1F on breast volume, although this became
stronger after further adjustment for hormone levels.
In conclusion, the CYP1A2*1F genotype significantly modified
the relationship between coffee consumption and breast volume in
non-users of hormonal contraception. It is likely that various
compounds in coffee exert a direct effect on the breast epithelium.
As breast volume is associated with breast cancer risk in lean
women, our finding is compatible with earlier reports of a
protective effect of coffee on breast cancer risk restricted to women
with the CYP1A2*1F C-allele.
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